Live Breaking News & Updates on Tiberend Strategic

Stay updated with breaking news from Tiberend strategic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BioEclipse to Participate in Biotech Showcase Digital During "J.P. Morgan Week 2021"


During Biotech Showcase Digital, registered conference participants will be able to watch a pre-recorded presentation by BioEclipse. Also, Dr. Contag will host virtual one-on-one meetings with registered investors and pharmaceutical and biotechnology companies via the conference s networking and scheduling platform, partneringONE®, to discuss BioEclipse s business and  highlight recent corporate achievements, as well as anticipated milestones in the clinical program for CRX100. BioEclipse has initiated an open-label, Phase 1 dose-escalation study to evaluate the safety, tolerability, and pharmacokinetic (PK) properties of CRX100 in advanced solid tumors that do not respond to standard of care, including triple-negative breast cancer, colorectal cancer, hepatocellular carcinoma, osteosarcoma, epithelial ovarian cancer, and gastric cancer. ....

Pam Contag , Miriam Miller , Stanford University , Eclipse Therapeutics , Biotech Showcase Digital , Biotech Showcase , Tiberend Strategic , Bioeclipse Therapeutics , மிரியம் மில்லர் , ஸ்டான்போர்ட் பல்கலைக்கழகம் , கிரகணம் சிகிச்சை , பயோடெக் காட்சி பெட்டி டிஜிட்டல் , பயோடெக் காட்சி பெட்டி ,